ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Summit Therapeutics Inc. (SMMT) stock declined over -6.38%, trading at $23.05 on NASDAQ, down from the previous close of $24.62. The stock opened at $24.00, fluctuating between $22.21 and $24.60 in the recent session.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Employees | 159 |
Beta | -0.46 |
Sales or Revenue | $0.00 |
5Y Sales Change% | -1% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |